Projects per year
Fingerprint Dive into the research topics where Yibin Kang is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 16 Similar Profiles
Neoplasm Metastasis
Medicine & Life Sciences
Neoplasms
Medicine & Life Sciences
Breast Neoplasms
Medicine & Life Sciences
Bone and Bones
Medicine & Life Sciences
Epithelial-Mesenchymal Transition
Medicine & Life Sciences
Neoplastic Stem Cells
Medicine & Life Sciences
Tumors
Chemical Compounds
Breast
Medicine & Life Sciences
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Projects 2008 2021
The Role of DACT1 in Bone Metastasis of Breast Cancer
NJ Commission on Cancer Research
1/1/19 → 12/31/20
Project: Research project
Jagged1-Dependent Tumor-stromal Interactions in Bone Metastasis
1/1/17 → 12/31/21
Project: Research project
BC151403: Functional Mechanism and Targeting of Metadherin in Breast Cancer
8/15/16 → 8/14/20
Project: Research project
The 17th Biennial Congress of the Metastasis Research Society
8/1/18 → 7/31/19
Project: Research project
Research Output 1996 2019
1
Citation
(Scopus)
A biomimetic 3D model of hypoxia-driven cancer progression
Liverani, C., De Vita, A., Minardi, S., Kang, Y., Mercatali, L., Amadori, D., Bongiovanni, A., La Manna, F., Ibrahim, T. & Tasciotti, E., Dec 1 2019, In : Scientific reports. 9, 1, 12263.Research output: Contribution to journal › Article
Open Access
Biomimetics
Neoplasms
Collagen
Epithelial-Mesenchymal Transition
Hypoxia
6
Citations
(Scopus)
Activin-like kinase 5 (ALK5) inactivation in the mouse uterus results in metastatic endometrial carcinoma
Monsivais, D., Peng, J., Kang, Y. & Matzuk, M. M., Feb 26 2019, In : Proceedings of the National Academy of Sciences of the United States of America. 116, 9, p. 3883-3892 10 p.Research output: Contribution to journal › Article
Open Access
Activins
Transforming Growth Factors
Endometrial Neoplasms
Uterus
Phosphotransferases
10
Citations
(Scopus)
Bone vascular niche E-selectin induces mesenchymal–epithelial transition and Wnt activation in cancer cells to promote bone metastasis
Esposito, M., Mondal, N., Greco, T. M., Wei, Y., Spadazzi, C., Lin, S. C., Zheng, H., Cheung, C., Magnani, J. L., Lin, S. H., Cristea, I. M., Sackstein, R. & Kang, Y., May 1 2019, In : Nature Cell Biology. 21, 5, p. 627-639 13 p.Research output: Contribution to journal › Article
E-Selectin
Blood Vessels
Neoplastic Stem Cells
galactoside 3-fucosyltransferase
Neoplasm Metastasis
4
Citations
(Scopus)
CD44 splice isoform switching determines breast cancer stem cell state
Zhang, H., Brown, R. L., Wei, Y., Zhao, P., Liu, S., Liu, X., Deng, Y., Hu, X., Zhang, J., Gao, X. D., Kang, Y., Mercurio, A. M., Goel, H. L. & Cheng, C., Feb 1 2019, In : Genes and Development. 33, 3-4, p. 166-179 14 p.Research output: Contribution to journal › Article
Neoplastic Stem Cells
Protein Isoforms
Breast Neoplasms
Alternative Splicing
Neoplasms
2
Citations
(Scopus)
Context-dependent EMT programs in cancer metastasis
Aiello, N. M. & Kang, Y., May 1 2019, In : Journal of Experimental Medicine. 216, 5, p. 1016-1026 11 p.Research output: Contribution to journal › Review article
Open Access
Neoplasm Metastasis
Neoplasms
Drug Resistance
Embryonic Development
Stem Cells
Press/Media
Secarna Pharmaceuticals, Firebrand Therapeutics Enter Co-Development Agreement for Novel Cancer Therapies [Syrian Arab News Agency]
9/7/18
1 item of Media coverage
Press/Media: Press / Media
Secarna Pharma enters co-development pact with Firebrand Therapeutics for novel cancer therapies
9/7/18
2 items of Media coverage
Press/Media: Press / Media
Secarna Pharmaceuticals And Firebrand Therapeutics Enter Into Co-Development Agreement For Novel Cancer Therapies
9/5/18 → 9/6/18
9 items of Media coverage
Press/Media: Press / Media
Secarna Pharmaceuticals, Firebrand Therapeutics Enter Co-Development Agreement for Novel Cancer Therapies
9/6/18
2 items of Media coverage
Press/Media: Press / Media
Secarna Pharmaceuticals and Firebrand Therapeutics enter into codevelopment agreement for novel cancer therapies
9/5/18
1 item of Media coverage
Press/Media: Press / Media